Drug Database
Back to search

United States· US:0088-2502_6be54063-6912-4810-b1c7-dfca969224d8

Apidra SoloStar

A insulin glulisine product containing insulin glulisine, registered in United States by sanofi-aventis U.S. LLC. The same ATC class is registered in 14 of our 19 countries.

ATC A10AB06US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedApidra SoloStarATCA10AB06REGISTER NO.US:0088-2502_6be54063…PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about insulin glulisineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Insulin glulisine is registered in 14 of 19 countries.

Countries holding a registration under ATC A10AB06 (insulin glulisine), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose
Search insulin glulisine products by name

Insulin glulisine · ATC A10AB06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
INSULIN GLULISINE
Manufacturer
sanofi-aventis U.S. LLC
Country
United States (US)
ATC code
A10AB06
ATC class
Insulin glulisine
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 4

  • ndc11
    0088250201
    1 SYRINGE, PLASTIC in 1 CARTON (0088-2502-01) / 3 mL in 1 SYRINGE, PLASTIC
  • ndc11
    0088250205
    5 SYRINGE, PLASTIC in 1 CARTON (0088-2502-05) / 3 mL in 1 SYRINGE, PLASTIC (0088-2502-00)
  • ndc11
    0088-2502-01
  • ndc11
    0088-2502-05

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for insulin glulisine.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check insulin glulisine against other medicinesHow interaction checks work

Insulin glulisine · interactions on record

434 records

  • 15 severe
  • 368 moderate
  • 50 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • PrednisoloneA07EA01moderate

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Insulin glulisine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin glulisine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Apidra, Apidra Solostar
  • Liechtenstein · Apidra, Apidra Solostar
  • Norway · Apidra, Apidra Solostar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c3d3df23-31cd-4da6-82f3-78add9cce1f9
GET /v1/drugs/c3d3df23-31cd-4da6-82f3-78add9cce1f9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "SUBCUTANEOUS",
  "source": "ndc",
  "strength": "100",
  "substance": "INSULIN GLULISINE",
  "productndc": "0088-2502",
  "dosage_form": "INJECTION, SOLUTION",
  "dea_schedule": null,
  "strength_unit": "[iU]/mL",
  "application_number": "BLA021629",
  "marketing_category": "BLA"
}
API referenceMCP serverPlans

See everything about insulin glulisine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console